VivoSim Labs (FRA:4OR) YoY EBITDA Growth: -147.67% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4OR VivoSim Labs Inc FRA:4OR
33 GF Score
Price €3.49
GF Value €12.30
! 6 Warning Signs
View Full Analysis

What is VivoSim Labs YoY EBITDA Growth?

VivoSim Labs FRA:4OR 33 YoY EBITDA Growth is -147.67% as of Mar. 2026. GuruFocus rates FRA:4OR with a GF Score™ of 33/100 and a GF Value™ of €12.30. The stock has 6 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. VivoSim Labs's YoY EBITDA Growth for the quarter that ended in Mar. 2026 was -147.67%.

VivoSim Labs's EBITDA per Share for the three months ended in Mar. 2026 was €-1.88.

VivoSim Labs YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for VivoSim Labs's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VivoSim Labs YoY EBITDA Growth Chart

VivoSim Labs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.09 -58.00 22.56 91.96 -225.93

VivoSim Labs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 220.23 61.33 45.50 59.71 -147.67
FRA:4OR
33GF Score
VivoSim Labs Inc FRA:4OR
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VivoSim Labs YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

VivoSim Labs's YoY EBITDA Growth for the fiscal year that ended in Mar. 2026 is calculated as:

YoY EBITDA Growth (A: Mar. 2026 )
=(EBITDA per Share (A: Mar. 2026 )-EBITDA per Share (A: Mar. 2025 ))/ | EBITDA per Share (A: Mar. 2025 ) |
=(-4.55--1.396)/ | -1.396 |
=-225.93 %

VivoSim Labs's YoY EBITDA Growth for the quarter that ended in Mar. 2026 is calculated as:

YoY EBITDA Growth (Q: Mar. 2026 )
=(EBITDA per Share (Q: Mar. 2026 )-EBITDA per Share (Q: Mar. 2025 )) / | EBITDA per Share (Q: Mar. 2025 )) |
=(-1.876-3.935)/ | 3.935 |
=-147.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -147.67% mean?
VivoSim Labs (FRA:4OR) has a YoY EBITDA Growth of -147.67% as of Mar. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for VivoSim Labs and its competitors.
Is VivoSim Labs' YoY EBITDA Growth too high?
VivoSim Labs' current YoY EBITDA Growth is -147.67%. Overall, VivoSim Labs has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' YoY EBITDA Growth compare to SLXN and CDT?
VivoSim Labs' YoY EBITDA Growth of -147.67% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for VivoSim Labs and its competitors. VivoSim Labs's current YoY EBITDA Growth is -147.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current YoY EBITDA Growth of -147.67%. The stock's GF Value™ is €12.30, compared to a current price of €3.49 — trading 71.6% below its estimated fair value. The current YoY EBITDA Growth is -147.67%. VivoSim Labs' overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current YoY EBITDA Growth is -147.67% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is VivoSim Labs (FRA:4OR) Overvalued in 2026?

Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued. The current stock price of €3.49 is trading 71.6% below its estimated GF Value™ of €12.30.

Key valuation signals for FRA:4OR:

  • YoY EBITDA Growth: -147.67%
  • GF Value™: €12.30 vs. price of €3.49 (71.6% below fair value)
  • GF Score™: 33/100 with 6 warning signs

No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

VivoSim Labs Business Description

Other Exchanges VIVS:USA
Address 11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
33GF Score

Get the complete analysis for FRA:4OR

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.49
Price
€12.30
GF Value